Global Novel Drug Delivery Systems (NDDS) Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global Novel Drug Delivery Systems (NDDS) Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Novel Drug Delivery Systems (NDDS): refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body to safely achieve its desired therapeutic effects. Novel drug delivery systems (NDDS) are innovative approaches that aim to enhance the efficacy, safety, and convenience of drug delivery.

Market Overview:

The latest research study on the global Novel Drug Delivery Systems (NDDS) market finds that the global Novel Drug Delivery Systems (NDDS) market reached a value of USD 94475.38 million in 2023. It’s expected that the market will achieve USD 61080.45 million by 2029, exhibiting a CAGR of -7.01% during the forecast period.

The positive impact of COVID-19 on the industry

The emergence of the COVID-19 pandemic has had a very significant impact on the market for novel drug delivery systems, as it has accelerated research into the development of effective treatments for COVID-19, such as vaccines, as well as marketable inputs. Novel coronavirus is an mRNA virus, and the difficulty of vaccine against virus lies in delivery, which refers to the carrier that protects the effective transportation of mRNA vaccine to the target and timely release. The commonly used vectors for mRNA vaccine delivery include Lipid nanoparticles (LNP), composites and polymer nanoparticles, dendritic cells (DC), peptides, and squalene-based cationic nanoemulsions. Among them, lipid nanoparticles (LNP) are currently the most widely used mRNA delivery technology in clinical practice, playing a pivotal role in effectively protecting mRNA and transporting it to the cytoplasm. Most of the COVID-19 vaccines used LNP as the vaccine carrier. And during the pandemic, governments have invested heavily in vaccine research and development in order to accelerate the process of vaccine research, such as, for example, in January 2020, Astrazeneca received more than $1.9 billion in funding from the US Department of Health's Biomedical Advanced Research and Development Agency (BARDA). For the development, production and delivery of the COVID-19 2021 vaccine at Oxford University. In addition, many studies have mentioned different novel drug delivery systems and the positive results of these studies could have a positive impact on the research market. In order to protect more people from the pandemic, many governments have lowered their regulatory policies so that new vaccines can be brought to market faster. So for the industry, the coronavirus pandemic is a positive.

The development of pharmacy and the pursuit of curative effect

With the rapid development of disease therapies, drug delivery technologies are also rapidly evolving to adapt to changing drug delivery needs. Decades ago, small molecule drugs were the mainstay of disease treatment, and new delivery challenges have emerged with the emergence of next-generation therapeutics such as peptides, proteins, monoclonal antibodies (mAbs), nucleic acids, and living cells , such as the stability of peptides and proteins, the efficiency of intracellular delivery of nucleic acids, the feasibility and scalability of live cell therapy, etc. Moreover, with the discovery of more insoluble drugs, the emergence of living drug forms such as cell therapy and gene therapy drugs, more and more drugs are difficult to exert their curative effect through traditional preparation methods. At this time, more cutting-edge preparation technologies are needed for drug delivery. According to the World Health Organization report on cancer, cancer is the leading cause of death worldwide and will kill nearly 10 million people in 2020, or nearly one in six deaths. Among them, targeted drugs have significant curative effects on a variety of malignant tumors due to their high specificity and low toxicity and side effects, and have become the mainstream of new anti-tumor drugs in the past ten years. According to studies and reports, there has been a substantial increase in cancer drug pipelines and related investments. The growth of downstream demand promotes the development of this industry.

Region Overview:

In 2022, the share of the Novel Drug Delivery Systems (NDDS) market in North America stood at44.42%.

Company Overview:

Pfizer, Inc. is one of the major players operating in the Novel Drug Delivery Systems (NDDS) market, holding a share of 20.19% in 2023.

Pfizer is a multinational pharmaceutical and biotechnology company with American origins and is one of the world's largest pharmaceutical companies, with a portfolio that includes pharmaceuticals and vaccines, as well as many of the world's best-known consumer healthcare products.

Moderna is a multinational pharmaceutical and biotechnology company headquartered in Cambridge, Massachusetts, United States, focused on cancer immunotherapy, including mRNA-based drug discovery, drug discovery, and vaccine technology.

Segmentation Overview:

Among different product types,PEGylated Proteins & Polypeptides segment is anticipated to contribute the largest market share in 2028.

Liposomal and Lipid Nanoparticle Liposomes are composed of cholesterol and natural non-toxic phospholipids, while lipid nanoparticles are nanoparticles composed of lipids. Both are advanced drug delivery systems designed to protect loaded drug molecules from external degradation.

PEGylated Proteins & Polypeptides As a widely used polymer carrier in PEC, polyethylene glycol is more reflected in changing the physical and chemical properties of the compound so that the prodrug can be activated after reaching the specific target of action, or changing the fat solubility or water solubility of small molecules to reduce the toxic side effects. It can be classified into passive targeted drug delivery systems and targeted drug delivery systems.

Microspheres Microsphere preparations refer to small spheres or spheroids formed by dissolving or dispersing drugs in natural or synthetic polymer materials, the particle size is generally in the range of 1-250μm. The drug is embedded or adsorbed on the surface of the polymer molecule by the microsphere, and then injected into the body by subcutaneous or intramuscular injection. The slow release of the drug can be realized by means of rapid release on the carrier surface, drug diffusion, polymer dissolution and degradation, etc., which can prolong the half-life of the drug.

Drug Conjugates Conjugated drug is a kind of compound that combines cytotoxic molecules with tumor-targeting components to make cytotoxic molecules targeted therapeutic drugs.

Application Overview:

By application, the Hospitals & Clinic segment occupied the biggest share from 2018 to 2022.

Hospitals & Clinic A hospital is a health-care facility that provides specialized medical and nursing care as well as medical supplies to patients. The most well-known form of the hospital is the general hospital, which usually carries an emergency department to handle urgent health issues. Based on the source of revenue, hospitals are categorized as general, specialized, or government. Drugs containing Liposomal and Lipid Nanoparticle are usually sold or used in hospitals.

Retail Pharmacy The definition of a retail pharmacy is a pharmacy acting as a retail store, selling drugs to patients. Retail pharmacists are responsible for dispensing medications correctly for customers to use at home, as well as educating the customers on their medications and answering questions the customers have. Drugs containing liposomal and lipid nanoparticle are also sold in retail pharmacy.

Key Companies in the global Novel Drug Delivery Systems (NDDS) market covered in Chapter 3:

Sun Pharmaceutical
Moderna
AstraZeneca PLC
Amgen
Gilead Sciences
Bayer HealthCare Pharmaceuticals
GlaxoSmithKline PLC
Takeda Pharmaceutical
Johnson & Johnson
CSPC
Pfizer, Inc.
Leadiant Biosciences
Kinyond
Pacira BioSciences
Ipsen
Alnylam
BMS
F. Hoffmann-La Roche AG
Luye Pharma Group
Novartis International AG

In Chapter 4 and Chapter 14.2, on the basis of types, the Novel Drug Delivery Systems (NDDS) market from 2019 to 2030 is primarily split into:

Liposomal and Lipid Nanoparticle
PEGylated Proteins & Polypeptides
Microspheres 
Drug Conjugates
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Novel Drug Delivery Systems (NDDS) market from 2019 to 2030 covers:

Hospitals & Clinic
Retail Pharmacy
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)